Carcinogenesis

This Article Abstract FREE Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to citation manager Search for citing articles in: ISI Web of Science (31) Request Permissions Google Scholar Articles by Tada, M. Articles by Moriuchi, T. Search for Related Content PubMed PubMed Citation Articles by Tada, M. Articles by Moriuchi, T. Social Bookmarking          What's this?

Carcinogenesis, Vol. 22, No. 3, 515-517, March 2001
© 2001 Oxford University Press

SHORT COMMUNICATION

Inactivate the remaining p53 allele or the alternate p73? Preferential selection of the Arg72 polymorphism in cancers with recessive p53 mutants but not transdominant mutants

Mitsuhiro Tada^1,4, Keiji Furuuchi¹, Masako Kaneda¹, Joe Matsumoto¹, Masato Takahashi¹, Atsuko Hirai¹, Yasuhide Mitsumoto², Richard D Iggo³ and Tetsuya Moriuchi¹

¹ Division of Cancer-Related Genes, Institute for Genetic Medicine, Hokkaido University, N-15 W-7, Kita-Ku, Sapporo, 060-0815, Japan,
² Third Department of Internal Medicine, Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, Kamigyo-Ku, Kyoto 602-8566, Japan and
³ Oncogene Group, Swiss Institute for Experimental Cancer Research (ISREC), Chemin des Boveresses 155, CH-1066 Epalinges, Switzerland

	Abstract

Top Abstract Introduction References

 
Several reports have noted epidemiological differences in the prevalence or prognostic significance of p53 mutants with arginine (R) or proline (P) at the codon 72 polymorphism (R72/P72) in certain cancer types, but the biological significance of these variants is unclear. The ability of p53 mutants to interact with and inactivate the p53 homolog p73 was recently reported to depend on the conformational state of the p53 protein and the residue at codon 72. Since the conformation of p53 mutants may influence their ability to transdominantly inhibit wild-type p53, we tested whether there was a correlation between the amino acid at codon 72 and the transdominance of p53 alleles found in tumors. The transdominance test was performed using a simple yeast transcription assay, and the amino acid at codon 72 was determined by sequencing. A total of 100 p53 mutants were tested. Compared with the germline frequency (R:P = 427:297), an extreme bias in favor of the R72 allele was observed with recessive mutants (R:P = 50:7, P < 0.0002), whereas no selection for the R72 allele was seen with transdominant mutants (R:P = 23:20). p53 and p73 are known to transactivate overlapping sets of target genes. We interpret the R72 bias with recessive mutants as evidence that decreased activation of p53 target genes provides a selective growth advantage to tumor cells during the stage of tumorigenesis in which a wild-type and mutant p53 allele coexist. We suggest that transdominant p53 mutants achieve this by inactivation of the remaining wild-type p53 allele, whereas recessive p53 mutants achieve it through inactivation of p73.

	Introduction

Top Abstract Introduction References

 
Mutation of the TP53 tumor suppressor gene itself is seen in more than half of all human cancers (1–3), and tumors retaining wild-type p53 often have mutations elsewhere in the p53 pathway or express viral proteins that inactivate p53 (4,5). A common polymorphism at residue 72 [Pro (P) or Arg (R)] has been linked to the ability of p53 to interact with cellular proteins and its susceptibility to degradation by the human papillomavirus E6 protein, possibly through an effect of the polymorphism on the conformation of the p53 protein (6,7). Following the first report of an increased risk of cervical cancer in R72/R72 homozygous individuals (6), many studies have been published showing both positive (8–11) and negative (3,12,13) correlations between polymorphic status and cancer occurrence. At present, the significance of the codon 72 polymorphism remains obscure, both in terms of cancer epidemiology and pathobiology.

Marin et al. recently described a difference in the biochemical activity of codon 72 polymorphic variants and postulated an enhanced pathological role for the R72 form in certain tumors (14). Some p53 mutants undergo a conformational change that promotes binding to the p73 protein and inhibition of p73 activity. The p53 mutant is a more potent inhibitor when it has arginine rather than proline at codon 72. Since p53 mutants with conformational changes are commonly recessive (meaning they do not inactivate wild-type p53 in a transdominant negative manner), we postulated that two functionally distinct pathways of p53 inactivation might exist: an R72-dependent one for recessive alleles and an R72-independent one for dominant alleles. To test this theory we examined whether the mutant p53 allele in our series of human cancers (15–17) was able to inhibit wild-type p53 transactivation in a yeast transdominance assay (18) and analyzed the status of the codon 72 polymorphism by sequencing (19) (Table I). Since the TP53 mutations were originally identified using a yeast p53 functional assay in which a large fragment of p53 cDNA including codon 72 is cloned as a single unit (18), we could readily determine the codon 72 sequence of the mutant p53 allele.

View this table: [in this window] [in a new window]   Table I. Alterations in TP53 alleles and their polymorphism at codon 72 in human cancers in respect to the transdominance of the mutants

 
We tested 97 missense mutations and three in-frame deletions found in human cancers (39 brain tumors, eight liver cancers, 11 colon cancers, 17 breast cancers, seven pancreatic cancers, 17 oral cancers and one skin cancer). We excluded chain-terminating mutations (premature stop codon and frameshift mutations) from this study because such mutants cannot interact with the remaining wild-type p53 allele, due to the lack of the C-terminal oligomerization domain at amino acids 324–355. The spectrum of TP53 mutations studied here was essentially identical to that in the IARC database (2), with respect to frequency of hotspot mutations, type of base changes (transition versus transversion) and distribution of the mutations. Codon 72 in the mutant alleles was arginine in 73 tumors and proline in 27. The R72 allele was thus significantly over-represented in the tumors compared with its germline frequency in the Japanese population (R:P = 427:297, P < 0.008, ² test) (20,21). This is consistent with the observation of Marin et al. that mutant alleles containing R72 are preferentially selected during tumorigenesis (14). Interestingly, examination of transdominance data revealed that this selection for R72 was true only of recessive mutant p53 alleles. There were 23 R72 and 20 P72 alleles in the transdominant group, compared with 50 R72 and only seven P72 alleles in the recessive group. Thus, there is an extreme bias in the selection of alleles between the two types of mutants (Table I; P < 0.0002, ² test). With transdominant mutants, the frequency of the R72 allele (53%) is close to the germline frequency (59%), suggesting that there is little, if any, selective advantage in retaining the R72 allele when the p53 mutant is transdominant. In contrast, with recessive mutants, the frequency of the R72 allele (88%) is much higher than the germline frequency (59%), suggesting that there is a strong advantage in retaining the R72 allele when the p53 mutant is recessive (P < 0.0002, ² test). This bias was seen with recessive mutants in every tumor type tested, although the number of samples is too small to reach statistical significance (R72:P72 in brain tumors 23:2; oral cancer 9:1; liver cancer 4:1; breast cancer 11:2; colon and pancreatic cancer, 4:0).

A simple model to explain this finding postulates that at the heterozygous stage in tumorigenesis a cell containing a transdominant mutant has reduced p53 activity, and consequently a growth advantage, irrespective of p73 activity. In contrast, a recessive mutant has near normal p53 activity at this stage, and is hence unlikely to be selected unless it can acquire some growth advantage by blocking p73 activity. Since the transdominant pathway requires only selection for a single variable it biases the p53 mutation spectrum towards transdominant mutants, which partly explains why hotspot mutants are commonly transdominant (22,23) (Table I). Failing that, p53 mutants resort to the subterfuge of hitting p73 in order to reduce the activation of p53 target genes (14). Since recessive mutants tend to be conformationally altered, our model is entirely consistent with the data of Marin et al. (14). Once the cell reaches the homozygous mutant stage by loss of the wild-type allele, a cell with a recessive, conformationally altered mutant has an advantage over its transdominant cousins because it can potentially achieve an even lower level of activation of p53 target genes—through inhibiting p73—than can most classic hotspot mutants. The 175H mutant is the striking exception to the rule that hotspot mutants tend to be conformationally intact (24). This mutant thus has the dual virtues of both inhibiting the wild-type p53 allele and inhibiting p73, perhaps explaining why it is so commonly found in tumors. The known properties of p73 lead us to suggest that the R72 selection in tumors with recessive p53 mutants reflects targeting of p73, but alternative models in which p53 targets other cellular growth regulatory proteins are also compatible with our data.

In conclusion, our finding supports the model proposed by Marin et al. and contributes one more piece to the puzzle of explaining the TP53 mutation spectrum seen in tumors. Since there is sufficient selective pressure to strongly bias the R72/P72 ratio in tumors, it is reasonable to expect that there may be differences in the behavior of tumors with one or other allele. Further studies to determine the biological mechanism and clinical consequences of selection of different codon 72 alleles are thus desirable.

	Notes

 
⁴ To whom correspondence should be addressed Email: m_tada{at}med.hokudai.ac.jp

	References

Top Abstract Introduction References

 

1. Harris,C.C. and Hollstein,M. (1993) Clinical implications of the p53 tumor-suppressor gene. N. Engl. J. Med., 329, 1318–1327.[Free Full Text]
2. Hainaut,P., Hernandez,T., Robinson,A., Rodriguez Tome,P., Flores,T., Hollstein,M., Harris,C.C. and Montesano,R. (1998) IARC Database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualisation tools. Nucleic Acids Res., 26, 205–213.[Abstract/Free Full Text]
3. Hainaut,P. and Hollstein,M. (2000) p53 and human cancer: the first ten thousand mutations. Adv. Cancer Res., 77, 81–137.[ISI][Medline]
4. Meek,D.W. (1999) Mechanisms of switching on p53: a role for covalent modification? Oncogene, 18, 7666–7675.[ISI][Medline]
5. Fulci,G., Ishii,N. and Van Meir,E.G. (1998) p53 and brain tumors: from gene mutations to gene therapy. Brain Pathol., 8, 599–613.[ISI][Medline]
6. Storey,A., Thomas,M., Kalita,A., Harwood,C., Gardiol,D., Mantovani,F., Breuer,J., Leigh,I.M., Matlashewski,G. and Banks,L. (1998) Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature, 393, 229–234.[Medline]
7. Thomas,M., Kalita,A., Labrecque,S., Pim,D., Banks,L. and Matlashewski,G. (1999) Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol. Cell. Biol., 19, 1092–1100.[Abstract/Free Full Text]
8. Sjalander,A., Birgander,R., Hallmans,G., Cajander,S., Lenner,P., Athlin,L., Beckman,G. and Beckman,L. (1996) p53 polymorphisms and haplotypes in breast cancer. Carcinogenesis, 17, 1313–1316.[Abstract/Free Full Text]
9. Kawajiri,K., Nakachi,K., Imai,K., Watanabe,J. and Hayashi,S. (1993) Germ line polymorphisms of p53 and CYP1A1 genes involved in human lung cancer. Carcinogenesis, 14, 1085–1089.[Abstract/Free Full Text]
10. Jin,X., Wu,X., Roth,J.A., Amos,C.I., King,T.M., Branch,C., Honn,S.E. and Spitz,M.R. (1995) Higher lung cancer risk for younger African-Americans with the Pro/Pro p53 genotype. Carcinogenesis, 16, 2205–2208.[Abstract/Free Full Text]
11. Murata,M., Tagawa,M., Kimura,M., Kimura,H., Watanabe,S. and Saisho,H. (1996) Analysis of a germ line polymorphism of the p53 gene in lung cancer patients; discrete results with smoking history. Carcinogenesis, 17, 261–264.[Abstract/Free Full Text]
12. Rosenthal,A.N., Ryan,A., Al-Jehani,R.M., Storey,A., Harwood,C.A. and Jacobs,I.J. (1998) p53 codon 72 polymorphism and risk of cervical cancer in UK. Lancet, 352, 871–872.[ISI][Medline]
13. Weston,A., Ling-Cawley,H.M., Caporaso,N.E., Bowman,E.D., Hoover,R.N., Trump,B.F. and Harris,C.C. (1994) Determination of the allelic frequencies of an L-myc and a p53 polymorphism in human lung cancer. Carcinogenesis, 15, 583–587.[Abstract/Free Full Text]
14. Marin,M.C., Jost,C.A., Brooks,L.A. et al. (2000) A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nature Genet., 25, 47–54.[ISI][Medline]
15. Kashiwazaki,H., Tonoki,H., Tada,M., Chiba,I., Shindoh,M., Totsuka,Y., Iggo,R. and Moriuchi,T. (1997) High frequency of p53 mutations in human oral epithelial dysplasia and primary squamous cell carcinoma detected by yeast functional assay. Oncogene, 15, 2667–2674.[ISI][Medline]
16. Tada,M., Iggo,R.D., Waridel,F., Nozaki,M., Matsumoto,R., Sawamura,Y., Shinohe,Y., Ikeda,J. and Abe,H. (1997) Reappraisal of p53 mutations in human malignant astrocytic neoplasms by p53 functional assay: comparison with conventional structural analyses. Mol. Carcinog., 18, 171–176.[ISI][Medline]
17. Takahashi,M., Tonoki,H., Tada,M. et al. (2000) Distinct prognostic values of p53 mutations and loss of estrogen receptor and their cumulative effect in primary breast cancers. Int. J. Cancer, 89, 92–99.[ISI][Medline]
18. Flaman,J.-M., Frebourg,T., Moreau,V. et al. (1995) A simple p53 functional assay for screening cell lines, blood and tumors. Proc. Natl Acad. Sci. USA, 92, 3963–3967.[Abstract/Free Full Text]
19. Marutani,M., Tonoki,H., Tada,M., Takahashi,M., Kashiwazaki,H., Hida,Y., Hamada,J., Asaka,M. and Moriuchi,T. (1999) Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme. Cancer Res., 59, 4765–4769.[Abstract/Free Full Text]
20. Yamashita,T., Yaginuma,Y., Saitoh,Y., Kawai,K., Kurakane,T., Hayashi,H. and Ishikawa,M. (1999) Codon 72 polymorphism of p53 as a risk factor for patients with human papillomavirus-associated squamous intraepithelial lesions and invasive cancer of the uterine cervix. Carcinogenesis, 20, 1733–1736.[Abstract/Free Full Text]
21. Minaguchi,T., Kanamori,Y., Matsushima,M., Yoshikawa,H., Taketani,Y. and Nakamura,Y. (1998) No evidence of correlation between polymorphism at codon 72 of p53 and risk of cervical cancer in Japanese patients with human papillomavirus 16/18 infection. Cancer Res., 58, 4585–4586.[Abstract/Free Full Text]
22. Brachmann,R.K., Vidal,M. and Boeke,J.D. (1996) Dominant-negative p53 mutations selected in yeast hit cancer hot spots. Proc. Natl Acad. Sci. USA, 93, 4091–4095.[Abstract/Free Full Text]
23. Inga,A., Cresta,S., Monti,P., Aprile,A., Scott,G., Abbondandolo,A., Iggo,R. and Fronza,G. (1997) Simple identification of dominant p53 mutants by a yeast functional assay. Carcinogenesis, 18, 2019–2021.[Abstract/Free Full Text]
24. Bullock,A.N., Henckel,J. and Fersht,A.R. (2000) Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy. Oncogene, 19, 1245–1256.[ISI][Medline]

Received September 4, 2000; revised November 3, 2000; accepted November 6, 2000.

CiteULike    Connotea    Del.icio.us    What's this?

This article has been cited by other articles:

				H. Lind, P. O. Ekstrom, D. Ryberg, V. Skaug, T. Andreassen, L. Stangeland, A. Haugen, and S. Zienolddiny Frequency of TP53 Mutations in Relation to Arg72Pro Genotypes in Non Small Cell Lung Cancer Cancer Epidemiol. Biomarkers Prev., October 1, 2007; 16(10): 2077 - 2081. [Abstract] [Full Text] [PDF]

				S Mitra, S Banerjee, C Misra, R K Singh, A Roy, A Sengupta, C K Panda, and S Roychoudhury Interplay between human papilloma virus infection and p53 gene alterations in head and neck squamous cell carcinoma of an Indian patient population J. Clin. Pathol., September 1, 2007; 60(9): 1040 - 1047. [Abstract] [Full Text] [PDF]

				N. Jain, V. Singh, S. Hedau, S. Kumar, M. K. Daga, R. Dewan, N. S. Murthy, S. A. Husain, and B. C. Das Infection of Human Papillomavirus Type 18 and p53 Codon 72 Polymorphism in Lung Cancer Patients From India Chest, December 1, 2005; 128(6): 3999 - 4007. [Abstract] [Full Text] [PDF]

				H. H. Nelson, M. Wilkojmen, C. J. Marsit, and K. T. Kelsey TP53 mutation, allelism and survival in non-small cell lung cancer Carcinogenesis, October 1, 2005; 26(10): 1770 - 1773. [Abstract] [Full Text] [PDF]

				Y. Hu, M. P. McDermott, and S. A. Ahrendt The p53 Codon 72 Proline Allele Is Associated with p53 Gene Mutations in Non-Small Cell Lung Cancer Clin. Cancer Res., April 1, 2005; 11(7): 2502 - 2509. [Abstract] [Full Text] [PDF]

				L. E. Mechanic, A. J. Marrogi, J. A. Welsh, E. D. Bowman, M. A. Khan, L. Enewold, Y.-L. Zheng, S. Chanock, P. G. Shields, and C. C. Harris Polymorphisms in XPD and TP53 and mutation in human lung cancer Carcinogenesis, March 1, 2005; 26(3): 597 - 604. [Abstract] [Full Text] [PDF]

				K. Scheckenbach, O. Lieven, K. Gotte, U. Bockmuhl, R. Zotz, H. Bier, and V. Balz p53 Codon 72 Polymorphic Variants, Loss of Allele-Specific Transcription, and Human Papilloma Virus 16 and/or 18 E6 Messenger RNA Expression in Squamous Cell Carcinomas of the Head and Neck Cancer Epidemiol. Biomarkers Prev., November 1, 2004; 13(11): 1805 - 1809. [Abstract] [Full Text] [PDF]

				A. Langerod, I. R. K. Bukholm, A. Bregard, P. E. Lonning, T. I. Andersen, T. O. Rognum, G. I. Meling, R. A. Lothe, and A.-L. Borresen-Dale The TP53 Codon 72 Polymorphism May Affect the Function of TP53 Mutations in Breast Carcinomas but not in Colorectal Carcinomas Cancer Epidemiol. Biomarkers Prev., December 1, 2002; 11(12): 1684 - 1688. [Abstract] [Full Text] [PDF]

				M. Furihata, T. Takeuchi, M. Matsumoto, A. Kurabayashi, Y. Ohtsuki, N. Terao, M. Kuwahara, and T. Shuin p53 Mutation Arising in Arg72 Allele in the Tumorigenesis and Development of Carcinoma of the Urinary Tract Clin. Cancer Res., May 1, 2002; 8(5): 1192 - 1195. [Abstract] [Full Text] [PDF]

				N. Tonisson, J. Zernant, A. Kurg, H. Pavel, G. Slavin, H. Roomere, A. Meiel, P. Hainaut, and A. Metspalu Evaluating the arrayed primer extension resequencing assay of TP53 tumor suppressor gene PNAS, April 16, 2002; 99(8): 5503 - 5508. [Abstract] [Full Text] [PDF]

This Article Abstract FREE Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to citation manager Search for citing articles in: ISI Web of Science (31) Request Permissions Google Scholar Articles by Tada, M. Articles by Moriuchi, T. Search for Related Content PubMed PubMed Citation Articles by Tada, M. Articles by Moriuchi, T. Social Bookmarking          What's this?

Online ISSN 1460-2180 - Print ISSN 0143-3334

Copyright © 2008 Oxford University Press

Oxford Journals Oxford University Press

• Site Map
• Privacy Policy
• Frequently Asked Questions

Other Oxford University Press sites: Oxford University Press Oxford Journals Japan American National Biography Booksellers' Information Service Children's Fiction and Poetry Children's Reference Corporate & Special Sales Dictionaries Dictionary of National Biography Digital Reference English Language Teaching Higher Education Textbooks Humanities International Education Unit Law Medicine Music Online Products Oxford English Dictionary Reference Rights and Permissions Science School Books Social Sciences Very Short Introductions World's Classics